Figure 4. The protective effects of 17DMAG in cachectic muscle wasting in C26 tumor-bearing mice.
(a) Left part : Bodyweight changes in normal control mice, 17DMAG or PU-H71-treated C26 tumor-bearing mice; veh1(17DMAG solvent) or veh2(PU-H71 solvent) treated C26 tumor-bearing mice. Day 0: tumor implantation. Day 7: 17DMAG injection began. Day 15: Terminal sacrifice day. Right part : Another experiment for survival rates of C26-tumor-bearing mice that received the treatment of 17DMAG or PU-H71 and their vehicle control. (b) Representative images of the hindlimbs of normal (left), C26 tumor-bearing (middle), and 17DMAG-treated C26 tumor-bearing (right) mice. (c) Grip strength was measured on day 14. (d) Tumor-free body mass, lean mass weight, and the tibialis anterior (TA), gastrocnemius (Gastroc), soleus, and extensor digitorum longus (EDL) muscles were weighed and compared after dissection with an electronic scale; Data represent the mean ± standard deviation (SD). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 denotes 17DMAG vs. C26; #p<0.05, ##p<0.01, ###p<0.001 denotes C26 vs. control.